CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
2024 更新：大 B 细胞淋巴瘤风险分层与管理的进展
英文原题：2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
查看英文原题
2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是一种异质性疾病，临床结局各异。我们对其分子构成的不断深入理解持续改善着风险分层，而基于人工智能和ctDNA的分析有潜力增强风险评估和疾病监测。R-CHOP和Pola-R-CHP用于一线治疗；嵌合抗原受体疗法（CAR-T）现已成为大多数原发性难治性疾病的新标准治疗；在复发/难治性情况下，CAR-T 和自体干细胞移植均被使用。在这篇综述中，我们总结了DLBCL的分类和管理，重点介绍了该领域的最新进展。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes.
Our understanding of its molecular makeup continues to improve risk stratification, and artificial-intelligence and ctDNA-based analyses have the potential to enhance risk assessment and disease monitoring.
R-CHOP and Pola-R-CHP are used in the frontline setting; chimeric antigen receptor therapy (CART) is now the new standard-of-care for most with primary refractory disease; both CART and autologous stem cell transplantation are utilized in the relapsed and refractory setting. In this review, we summarize the classification and management of DLBCL with an emphasis on recent advances in the field.
论文信息
- 作者
- Tavakkoli M、Barta SK
- 单位
- Department of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.United States
- 文献类型
- 综述
- 期刊
- American journal of hematology2023 Nov
- 原文标识
- PubMed 37647158 · DOI 10.1002/ajh.27075